Greetings from Perth. I am over in Western Australia to speak at an event on Thursday called Broker Meets Biotech. I love coming to Perth because people here are optimistic and laid back. It's like the California of Australia.
AdAlta (ASX: 1AD) is a great story for the folks in WA to look at. Monoclonal antibodies are now a >US$70bn drug class. AdAlta with its i-bodies are, I believe, one of the Next Big Things in the monoclonal antibody revolution in medicine.
Click here to check out the research.